Clostridium difficile infection (CDI) is associated with increased mortality in inflammatory bowel disease (IBD), but the risk of colectomy is variable and has not been adequately studied.
SUMMARY Background
Clostridium difficile infection (CDI) is associated with increased mortality in inflammatory bowel disease (IBD), but the risk of colectomy is variable and has not been adequately studied.
Aim
To perform a systematic review and meta-analysis to assess the impact of CDI on colectomy risk in IBD.
Methods
Multiple databases were searched systematically for observational studies reporting colectomy risk in IBD, stratified by the presence of CDI, and the duration of follow-up (short term 3 months, and long term at least 1 year). Weighted summary estimates were calculated using generalised inverse variance with random-effects model. Study quality was assessed using the Newcastle-Ottawa scale.
Results
Twelve observational studies were identified and included 35 057 IBD patients with CDI, and 929 259 without CDI. CDI did not increase the short-term colectomy risk in IBD patients overall (10 studies) (OR: 1.35; 95% CI: 0.68-2.67), or in patients with ulcerative colitis (nine studies) (OR: 1.20; 95% CI: 0.39-3.76). In contrast, CDI was associated with higher longterm colectomy risk in patients with IBD overall (five studies) (OR: 2.23; 95% CI: 1.18-4.21), and in patients with ulcerative colitis (four studies) (OR: 2.96; 95% CI: 1.19-7.34). The results were stable in subgroups stratified by recruitment period, hospitalisation status and geographical location. All studies were at least of moderate quality. The results were limited in the ability to compare IBD severity and the type of anti-microbial therapy.
Conclusion
Based on 12 observational studies with at least moderate quality, Clostridium difficile infection appears to increase colectomy risk in IBD in the long-but not short-term. 
INTRODUCTION
The past two decades have witnessed a substantial rise in the incidence and severity of Clostridium difficile infection (CDI) 1 with CDI surpassing methicillin resistant
Staphylococcus aureus as the leading cause of nosocomial infection. 2 The incidence has increased in hospital and community settings, and a hypervirulent strain (B1/ NAP1/027) associated with increased morbidity and mortality has emerged. 1, 3 Inflammatory bowel disease (IBD) is an independent risk factor for CDI even in the absence of traditional risk factors such as antibiotic exposure and hospitalisation. [4] [5] [6] This is likely related to the frequent requirement of immunosuppressive medications, increased exposure to health-care facilities, alterations in the gut microbiome, and the intrinsically deregulated mucosal immune system associated with IBD.
The incidence of CDI in IBD is increasing, possibly at a higher rate than in the general population. 4, 7, 8 Two single centre studies found a 2-3 fold increase in CDI among IBD patients in the late 1990s and early 2000s. 4, 9 Similarly, large administrative database studies from the National Inpatient Sample (NIS) have corroborated these findings. 5, 7 Recent studies have demonstrated a prevalence of CDI ranging from 6% to 9% among IBD patients hospitalised with a disease flare.
10-12
In the general hospitalised population, CDI has a negative clinical impact resulting in increased rates of colectomy and mortality compared to patients without CDI. 1 Similarly, CDI has consistently been associated with higher mortality risk in patients with IBD. 7, [12] [13] [14] [15] However, the impact of CDI on the risk of colectomy in IBD is not clear due to conflicting associations between studies. A few studies have demonstrated an increase risk of colectomy with CDI in IBD patients, 7, [15] [16] [17] while others have either shown an inverse relationship or no effect at all. [18] [19] [20] A recent meta-analysis concluded that CDI was associated with higher surgical rates in ulcerative colitis (UC) 21 ; however, multiple key studies were not analysed, including several recently published studies. 5, 15, 18, [22] [23] [24] [25] Moreover, substantial variability in follow-up period between studies limited the comparability of studies contained in this review. Therefore, the aim of our systematic review and meta-analysis was to assess the risk of colectomy in IBD patients with and without CDI, stratified by short-and long-term follow-up.
METHODS
This systematic review and meta-analysis was conducted with guidance from the Cochrane handbook 26 and reported according to the Preferred Reporting Items for Systematic Reviews and meta-analyses (PRISMA) guidelines. 27 The process followed an a priori established protocol. Two investigators (CL and RT) independently performed an initial screening of titles and abstracts. Relevant studies were reviewed in full to determine eligibility for inclusion according to pre-determined criteria. The coefficient of agreement between reviewers for article selection (k = 0.52) was moderate. Disagreement was resolved through evaluation by a third investigator (JM) and consensus.
Study selection
Cohort, cross-sectional and case-control studies were deemed acceptable. Inclusion criteria included: (i) patients with IBD (UC, CD or IBD undifferentiated), and (ii) reported rates of colectomy stratified by CDI exposure. Studies were excluded if (i) they lacked CDI-negative IBD controls, (ii) included surgeries other than colectomy, (iii) included paediatric patients only, (iv) were not written in the English language, (v) lacked adequate sample size (less than 10 patients with IBD and CDI). In situations where studies contained substantial overlapping data from the same patient population (greater than 2 years of overlapping data), data from the most comprehensive study (greatest number of patients) was included. In studies with a minor degree of overlap (less than 2 years overlap), both datasets were included with a pre-planned sensitivity analysis.
Data extraction and study quality Data abstraction was performed independently by two investigators (CL and RT) and confirmed by a third investigator (JM). The data included: (i) study characteristics -primary author, year of publication/time period of study, geographic location, paper/abstract, and study design, (ii) patient and IBD disease characteristics -age, gender, percentage of IBD patients by IBD subtype (UC vs. CD), hospitalisation status (in-patient vs. out-patient), disease severity, IBD medications (including systemic steroids, immunomodulators and biologic therapy), and comorbidity scores, (iii) CDI characteristics -method of diagnosis (ELISA, EIA, cytotoxicity assay, stool PCR), (iv) outcome assessment -follow-up time, colectomy rate for the overall IBD cohort and stratified by UC and CD subgroups.
The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS) modified for this study. 28 Studies were scored across three categories: selection (four questions), comparability of study groups (two questions), and ascertainment of the outcome of interest (three questions) with a maximum of one point per question. Study quality was defined as low, moderate and high, based on scores of 0-3, 4-6 and 7-9 respectively.
Clinical outcomes assessed
The primary outcome was the risk of colectomy in IBD patients with CDI compared to those without CDI, stratified by follow-up time. Short-term follow-up was defined as within the index hospitalisation or within 3 months from the time of CDI diagnosis, and long-term follow-up was defined as having at least 1-year or longer of follow-up from the time of CDI diagnosis.
The following pre-planned subgroup analyses were performed to identify potential sources of heterogeneity and to assess for stability of association: (i) UC patients vs. CD patients, (ii) administrative database vs. non-administrative data base studies and (iii) year of publication before 2005 and 2005 or later. In addition, sensitivity analysis was preformed for: (i) hospitalised patients only, (ii) high quality studies (NOS score greater than 6) (iii) study country of origin (within or outside North America) and (iv) by eliminating overlapping studies. Lastly, short and long-term mortality risk was also evaluated.
Statistical analyses
Statistical analysis was performed using RevMan 5.3. Risk of colectomy was determined by comparing the surgical rates between CDI-positive and CDI-negative IBD patients overall for short-and long-term follow-up periods and when available, stratified by IBD subtype (UC and CD). Adjusted odds ratios, when available, or odds ratios reported by the study were used in the analysis. Following this, weighted summary estimates were calculated using generalised inverse variance with randomeffects model as described by DerSimonian and Laird. 29 Summary estimates are presented as ORs with 95% confidence intervals (CI). Summary estimates of mortality risk were also calculated in this manner.
To estimate the proportion of total variation across studies due to heterogeneity rather than chance, the I 2 statistic was calculated. Values of <30%, 30-59%, 60-75% and >75% were suggestive of low, moderate, substantial and considerable heterogeneity respectively. 30 Sources of heterogeneity were explored by multiple pre-planned subgroup analysis (as described above). Qualitative estimation of publication bias was performed through visual inspection of funnel plots ( Figure S1 ).
RESULTS

Search results
Our search identified 1824 citations, 12 of which met the pre-defined study criteria and were included in our systematic review and meta-analysis. Figure 1 summarises the process of study identification, inclusion and exclusion. Patient recruitment spanned from 1998 to 2013, and the studies were published between 2008 and 2016. All studies were performed retrospectively. Eight studies were published as full-length manuscripts, and four were published in conference proceedings. In addition, six studies were single-centre studies and six were population-based studies that used administrative health data. Nine studies were conducted in North America, two were conducted in Europe, and one was performed in Asia.
Patient characteristics and CDI diagnosis
Data were available for a total of 35 057 IBD patients with CDI and 929 259 IBD controls without CDI. The baseline characteristics of these patients are summarised in Table 1 . The majority of studies (n = 10) assessed data from hospitalised patients. The remaining studies (n = 2) contained a mix of ambulatory and hospitalised patients. In the single-centre studies, CDI was diagnosed by ELISA/EIA in five studies, and was unclear in one study. The majority of administrative database-based studies (n = 4) used ICD9 codes to identify CDI positive patients. Two studies used ICD10 codes, of which one internally validated the codes with their specific patient population.
Short-term follow-up, within the index hospitalisation or within 3 months of CDI diagnosis, was assessed in 10 studies, whereas long-term follow-up, with at least 1 year of follow-up after the CDI diagnosis was assessed in five studies.
Lastly, 10 studies reported colectomy risk for patients with UC only and three studies for CD only.
Risk of short-term colectomy:
Data from 12 individual time points from 10 studies reported the rates of short-term colectomy. There was no difference in the risk of colectomy between IBD patients with CDI compared to those without CDI (OR:
1.35; 95% CI: 0.68-2.67) (Figure 2 ). Considerable heterogeneity was observed in the overall analysis (I 2 = 97%).
When patients were stratified by IBD type, CDI was not associated with increased surgery risk in patients with UC (OR: 1.20; 95% CI: 0.39-3.76) or CD (OR: 1.38; 95% CI: 0.72-2.66).
Subgroup and sensitivity analyses
The conclusions were not affected by restricting the analysis to hospitalised patients and studies performed in North America (Table 2) . Similarly, CDI was not associated with an increased risk of short-term colectomy in any of our pre-defined subgroups based on recruitment Nguyen et al. (Table 2) . A weak signal for colectomy risk was observed (OR: 1.44; 95% CI: 1.01-2.05) in a subgroup that included only high-quality studies.
Risk of long-term colectomy
Five studies reported the risk of colectomy with longterm follow-up. On meta-analysis, the risk of colectomy was significantly higher for IBD patients with CDI, compared to patients without CDI (OR: 2.23; 95% CI: 1.18-4.21) (Figure 3 ). Substantial heterogeneity was observed in the overall analysis (I 2 = 75%). When the analysis was restricted to patients with UC, the risk of colectomy with long-term follow-up remained significant for the CDI positive group (OR: 2.96; 95% CI: 1.19-7.34). The conclusions were not affected by restricting the analysis to hospitalised patients, and high-quality studies according to our predefined NOS criteria. On subgroup analysis, the increased risk of colectomy remained significant regardless of the study recruitment year (before 2005 vs. 2005 and later), study design (institutional-based vs. administrative database studies) and study country of origin (within or outside of North America) ( Table 3) . Study quality and publication bias Study quality was assessed by the NOS (Table S1 ). Five of 12 studies were of moderate quality, and seven were high quality. The median NOS score was 6.45 (range, 5-8) of a maximum of 9. Notably, only four studies used laboratory confirmation of CDI status in all cases and controls. 16, 18, 19, 32 adequate follow-up, only 1 study specifically commented on the rate of patients lost to follow-up. 12 There was no evidence of publication bias based on visual examination for funnel plot asymmetry ( Figure S1 ).
Mortality risk
DISCUSSION
Clostridium difficile infection is as an important cause of symptomatic IBD flares and is associated with increased length of hospital stay and mortality. 5, 7, 13, 17, 22 Although colectomy risk has been consistently reported in non-IBD populations, the incremental impact of CDI on colectomy risk in IBD is not as well defined. Furthermore, the reported short-term association between CDI and IBD has differed considerably between studies. This study found that CDI is associated with an increased risk of colectomy in IBD when assessed over a period of at least 1 year but not in the short term.
Patients were stratified by follow-up duration, as it was felt short-term outcomes would better reflect a direct impact of CDI. CDI was not associated with short-term colectomy risk in the IBD population, which is in sharp contrast to that of the general population, where it has been consistently associated with greater colectomy risk. 1, 33 This may reflect the relative reversible nature of inflammation from an infectious exacerbation compared to an idiopathic flare in individuals with active IBD. This may also result from a greater burden of Clostridium difficile colonisation, rather than active CDI, in IBD compared to the general population as was reported by Clayton and colleagues. 34 Alternatively, an increased awareness of infectious exacerbations in IBD may result in earlier detection and administration of effective anti-microbial therapy leading to improved outcomes. In contrast to short-term follow-up, our findings suggest CDI may be a risk factor for colectomy when assessed over a longer duration, although substantial heterogeneity between studies and possible residual confounding within individual studies precludes any definitive conclusion. Furthermore, the studies assessing long-term risk of colectomy assessed cumulative colectomy risk without stratifying their data by short and long term. Therefore, we were unable to determine the proportion of colectomies in these studies that occurred before or after 3 months. The potential reasons for greater long-term colectomy risk with CDI requires further elucidation as it is difficult to envision a causal relationship between Clostridium difficile and colectomy risk long after the organism has been eradicated. Most studies did not directly assess for recurrent infection, which can occur in up to 34% of patients with IBD. 11, 35, 36 It is also possible that Clostridium difficile is able to alter the natural history of IBD by modifying mucosal immune mechanisms and/or the gut microbiome. Indirect support for this concept has been demonstrated by studies, which found an increased risk of readmission and requirement for escalation in immunosuppressive therapy in IBD patients following CDI. 16, 37 An equally plausible explanation is that CDI is simply a surrogate marker of underlying IBD severity; whereby patients with a severe phenotype are more likely to acquire CDI through repeated hospitalisations, antibiotic exposure, extensive colonic IBD, reduced microbial diversity from active inflammation and exposure to immunosuppressive medications. 38 Ananthakrishnan and colleagues have also identified mutual genetic risk alleles associated with CDI and IBD susceptibility.
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A positive finding from this study was the stability of our results across the majority of subgroups and within our sensitivity analysis. Controlling for studies that reported the risk of colectomy in hospitalised patients only was important as ambulatory and hospitalised patients are likely to have inherent difference in the risk of colectomy. Controlling for studies performed in North America was also important, as there may be regional differences in clinical practices. Similarly, controlling for patients with UC only was important, as we were unable to control for colonic IBD in patients with CD. Administrative database studies rely upon diagnostic codes for case ascertainment, rather than through direct laboratory confirmation. Although a previous study determined that ICD-9 coding is reasonably sensitive and highly specific for predicting CDI, 40 the stability of our results when restricting studies to single-centre nondatabase studies suggests that the inclusion of database studies is unlikely to have introduced substantial bias. Interestingly, a weak signal for short-term colectomy risk was observed in a subgroup that included only highquality studies. Given that this was the only subgroup that was statistically associated with an increased risk of colectomy, further studies are needed to confirm these findings and to determine additional subgroups of IBD patients that are at risk for short-term colectomy. Our study contained a number of notable limitations. First, our study contained substantial heterogeneity that we were unable to account for by subgroup or sensitivity analysis. No consistent differences in the way data were reported or difference in time to colectomy were detected. Differences in patient populations, immunosuppressive treatment exposure, and anti-microbial therapy may have accounted for the heterogeneity. Furthermore, most did not directly compare endoscopic and/or clinical severity. Not only could this have impacted colectomy risk directly, but it may have also introduced a detection bias if a disproportionate number of patients with severe disease underwent investigations for CDI. Second, many studies did not control for elective admissions for colectomy, which may have artificially increased the colectomy rate in the non-CDI population. Third, only two studies reported rates of biologic therapy. It is possible that reluctance to use biologics in the presence of a virulent infection led to higher colectomy rates. Finally, we were unable to assess the proportion of patients with the hypervirulent Clostridium difficile ribotype B1/NAP1/027 or control for secular trends in CDI management. Both of these factors impact colectomy risk 4, 41 and differences in either of these factors may have contributed to the heterogeneity among studies.
It is important to consider that our study assessed symptomatic patients who may have otherwise been in clinical remission in the absence of CDI. Therefore, the lack of short-term colectomy risk should not be interpreted as CDI having a benign course in IBD. This is further substantiated by the increased risk of mortality associated with CDI. To date, no studies have used a combined endpoint of colectomy and mortality. Future studies should use a co-primary endpoint combining colectomy and mortality when assessing the impact of CDI in IBD. The optimal management of CDI in IBD continues to evolve and controversies persist over the optimal anti-microbial therapy, the safety of concomitant immunosuppression, and the ideal placement of novel therapies such as faecal microbial therapy into our treatment algorithm. Future studies are required to determine the optimal treatment for IBD in the setting of CDI and to determine if this may alter long-term risk of colectomy.
In conclusion, our study demonstrates that while CDI does not appear to increase the risk of short-term colectomy in IBD, it is associated with long-term colectomy risk and increased mortality. This study serves as an important reminder to consider IBD patients with CDI as a high-risk population, warranting close follow-up, appropriate CDI treatment and potentially aggressive control of the underlying inflammation. Further studies are needed clarify the mechanism(s) leading to this increased risk of colectomy, so that appropriate treatment strategies can be implemented.
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